Holen Sie sich die Stockscreener-App
4.75
4.86%
0.22
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAMP?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.53
Offen:
$4.54
24-Stunden-Volumen:
105.21K
Relative Volume:
0.47
Marktkapitalisierung:
$246.62M
Einnahmen:
$3.50M
Nettoeinkommen (Verlust:
$-80.40M
KGV:
-1.8475
EPS:
-2.5711
Netto-Cashflow:
$-29.83M
1W Leistung:
-10.88%
1M Leistung:
+6.74%
6M Leistung:
+58.33%
1J Leistung:
-7.77%
1-Tages-Spanne:
$4.54
$4.99
1-Wochen-Bereich:
$4.44
$5.89
52-Wochen-Spanne:
$1.305
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Firmenname
Camp 4 Therapeutics Corp
Sektor
Branche
Telefon
617-651-8867
Adresse
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.75 | 246.62M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-27 | Eingeleitet | Wedbush | Outperform |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
| 2022-08-16 | Hochstufung | Craig Hallum | Hold → Buy |
| 2021-12-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2021-09-24 | Bestätigt | Craig Hallum | Buy |
| 2021-06-25 | Bestätigt | Craig Hallum | Buy |
| 2020-12-18 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-05 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-01 | Bestätigt | Craig Hallum | Buy |
| 2019-03-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Hochstufung | Craig Hallum | Hold → Buy |
| 2018-12-14 | Bestätigt | B. Riley FBR | Buy |
| 2018-12-11 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Eingeleitet | Goldman | Neutral |
| 2018-10-15 | Eingeleitet | Jefferies | Hold |
| 2018-09-28 | Bestätigt | Craig Hallum | Hold |
| 2018-04-27 | Bestätigt | Craig Hallum | Hold |
| 2018-03-08 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-02-16 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
Alle ansehen
Camp 4 Therapeutics Corp Aktie (CAMP) Neueste Nachrichten
CAMP4 Therapeutics Corporation Files Form 8-K for NASDAQ Listing – Company Details and Key Information (March 2026) - Minichart
CAMP4 Appoints Michael MacLean to its Board of Directors - Bitget
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation - Investing.com
CAMP4 Therapeutics Adds Veteran CFO MacLean to Board - TipRanks
Camp4 Therapeutics appoints Michael MacLean as director, joins Audit and Compensation Committees - TradingView
Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push - Traders Union
New CAMP4 (NASDAQ: CAMP) director MacLean joins, receives option grant - Stock Titan
If You Invested $1,000 in Camp4 Therapeutics Corp. (CAMP) - Stock Titan
Camp4 Therapeutics (CAMP) holder Enavate cuts stake to 4.8% of shares - Stock Titan
EVTL Technical Analysis & Price Forecast - Intellectia AI
Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP) - Seeking Alpha
William Blair Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
Biotech firm CAMP4 lines up 3 healthcare investor events - Stock Titan
Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target - Investing.com India
Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target By Investing.com - Investing.com Australia
CAMP4 Highlights 2025 Results and SYNGAP1 Program Progress - TipRanks
Camp4 Therapeutics Corp posts full year 2025 financial results and unveils corporate update - Traders Union
Camp4 Therapeutics Earnings Review: Q4 Summary - Benzinga
Camp4 Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights - GlobeNewswire
Guidance Update: What is Camp4 Therapeutics Corporations book value per shareEarnings Risk Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Regulatory RNA strategy presented for gene expression, Camp4 Therapeutics Corp outlines - Traders Union
Camp4 Therapeutics Corporation announced that it has received $100.167156 million in funding from Janus Henderson Investors, Balyasny Asset Management L.P., Vivo Capital, LLC, Adage Capital Management, L.P., Trails Edge Capital Partners, LLC, SYN - marketscreener.com
Camp4 Therapeutics Corp unveils ASO approach to boost gene expression in SYNGAP1 treatment - Traders Union
Camp4 Therapeutics Corp commits to new therapies for rare and neurological diseases - Traders Union
CAMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
RBOT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA) - The Globe and Mail
Merger Talk: Whats next for Mondelez International Inc stockQuarterly Profit Review & Verified Chart Pattern Signals - baoquankhu1.vn
Camp4 Therapeutics Corp engages with SYNGAP1 community in Poland family day event - Traders Union
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
Cantor Fitzgerald Remains a Buy on CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
Market Moves: Can AUUDW maintain its current growth rateEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
CNTY PE Ratio & Valuation, Is CNTY Overvalued - Intellectia AI
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How Camp4 Therapeutics Corporation stock reacts to job market dataMarket Sentiment Report & Weekly Chart Analysis and Guides - mfd.ru
Fed Meeting: Will Camp4 Therapeutics Corporation face regulatory challenges2025 Investor Takeaways & Low Volatility Stock Suggestions - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS) - The Globe and Mail
Risk Check: Is TACT undervalued by DCF analysisQuarterly Portfolio Review & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Is Camp4 Therapeutics Corporation stock a buy in volatile marketsJuly 2025 Update & Stepwise Trade Signal Implementation - mfd.ru
Is Camp4 Therapeutics Corporation being accumulated by smart money2025 Market WrapUp & AI Driven Stock Movement Reports - mfd.ru
Can Camp4 Therapeutics Corporation ride the EV waveMarket Trend Review & Free Verified High Yield Trade Plans - mfd.ru
BRID PE Ratio & Valuation, Is BRID Overvalued - Intellectia AI
WRAP PE Ratio & Valuation, Is WRAP Overvalued - Intellectia AI
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
SY PE Ratio & Valuation, Is SY Overvalued - Intellectia AI
FMR LLC Increases Stake in Camp4 Therapeutics Corp: A Strategic Move in Biotechnology - GuruFocus
10 Best Online Therapy Platforms In 2026: Tested & Reviewed - Forbes
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Finanzdaten der Camp 4 Therapeutics Corp-Aktie (CAMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):